- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | P3 Health Partners just downgraded at BTIG | 1 | Seeking Alpha | ||
| 01.04. | Earnings call: P3 Health Partners reports growth and positive 2024 outlook | 1 | Investing.com | ||
| 01.04. | P3 Health Partners falls after BTIG downgrades to 'neutral' | 1 | Reuters | ||
| 28.03. | P3 Health Partners: Q4 Earnings Insights | 2 | Benzinga.com | ||
| 28.03. | P3 Health Partners Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 28.03. | P3 Health Partners GAAP EPS of -$0.22 misses by $0.11, revenue of $346.9M beats by $44.17M | 1 | Seeking Alpha | ||
| 28.03. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | P3 Health Partners' Earnings: A Preview | 1 | Benzinga.com | ||
| 15.03. | P3 Health to report Q4 and full year 2023 earnings on March 28 | 2 | Investing.com | ||
| 12.03. | P3 Health Partners Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 12.03. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.01. | P3 Health Partners rise on upbeat FY24 revenue forecast | 2 | Reuters | ||
| 10.01. | Why Health Management Company P3 Health Partners Shares Are Up Today | 1 | Benzinga.com | ||
| 10.01. | P3 Health Partners reaffirms 2023 guidance, sees 2024 revenue above estimates | 1 | Seeking Alpha | ||
| 10.01. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.01. | P3 Health Partners Reaffirms 2023 Guidance, Sees 2024 Revenue Above View; Stock Up | 1 | RTTNews | ||
| 10.01. | P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024 | 171 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, is participating in... ► Artikel lesen | |
| 12.11.23 | P3 Health Partners Inc. (PIII) Q3 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 09.11.23 | P3 Health Partners reports improved Q3 financial results | 1 | Investing.com | ||
| 08.11.23 | P3 Health Partners GAAP EPS of -$0.12 | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 12,582 | -0,66 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| NANO-X IMAGING | 8,940 | +0,22 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| BUTTERFLY NETWORK | 0,780 | +10,56 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
| GOODRX | 7,190 | +1,55 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,230 | +1,24 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
| CARMAT | 3,145 | -0,47 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
| HYPERFINE | 0,845 | +1,68 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 32,040 | -1,42 % | Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report | ||
| MIMEDX | 6,265 | +0,32 % | Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers | ||
| BIOMERICA | 0,665 | -2,21 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results |
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| ATRION | 370,00 | -6,09 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| ATRICURE | 23,170 | +2,48 % | AtriCure upgraded at Oppenheimer on valuation | ||
| TALKSPACE | 3,120 | +1,30 % | Talkspace Announces Third Quarter 2023 Results | B2B payor revenue grew 132% year-over-year 3Q 2023 Operating expenses of $24.0 million, down 30% year-over-year Reduced Net Loss to $4.4 million and Adjusted EBITDA1 loss to $2.8 million, an improvement... ► Artikel lesen | |
| OUTSET MEDICAL | 2,400 | +0,84 % | FDA labels Outset Medical recall of Tablo hemodialysis system as Class I | ||
| CASTLE BIOSCIENCES | 20,340 | +4,25 % | Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer | If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes... ► Artikel lesen |
Das Unternehmen P3 HEALTH PARTNERS INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,446 Euro und damit -7,02 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
